Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-96431077feaab94e628cf99788cf8afd"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-96431077feaab94e628cf99788cf8afd"/>
<resource>
<Composition>
<id value="composition-en-96431077feaab94e628cf99788cf8afd"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-96431077feaab94e628cf99788cf8afd"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-96431077feaab94e628cf99788cf8afd</b></p><a name="composition-en-96431077feaab94e628cf99788cf8afd"> </a><a name="hccomposition-en-96431077feaab94e628cf99788cf8afd"> </a><a name="composition-en-96431077feaab94e628cf99788cf8afd-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1524/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - vazkepa</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/20/1524/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp96431077feaab94e628cf99788cf8afd"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - vazkepa"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Vazkepa is and what it is used for</li><li>What you need to know before you take Vazkepa</li><li>How to take Vazkepa</li><li>Possible side effects</li><li>How to store Vazkepa</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What vazkepa is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What vazkepa is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Vazkepa contains the active substance icosapent ethyl, a highly purified omega-3 fatty acid from fish oil.</p><p>Vazkepa lowers levels of triglycerides (types of fat) in the blood and it is used with a statin medicine (that lowers blood cholesterol) to prevent cardiovascular events, such as:</p><ul><li>heart attack</li><li>stroke</li><li>death from heart or vascular disease</li></ul><p>Vazkepa is used in adults with high blood triglycerides who already have heart disease or have diabetes and other conditions that put them at a higher risk of cardiovascular events.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take vazkepa"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take vazkepa"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Vazkepa</p><ul><li>If you are allergic to icosapent ethyl, soya or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions<br/>Talk to your doctor or pharmacist before taking Vazkepa:</p><ul><li>If you are allergic to fish or to shellfish.</li><li>If you have problems with your liver.</li><li>If you have problems with irregular heartbeat (atrial fibrillation or flutter).</li><li>If you take an anticoagulant medicine (which prevents blood from clotting), medicines that inhibit platelets in the blood or are at risk of bleeding.</li></ul><p>If any of the above applies to you, talk to your doctor.</p><p>Blood tests During your treatment your doctor may carry out blood tests to check for any problems with your liver and to check how your blood is clotting.</p><p>Children and adolescents Do not give this medicine to children and young people below 18 years of age because it has not been studied in these people.</p><p>Other medicines and Vazkepa Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>If you are taking other medicines at the same time as Vazkepa that affect how your blood clots, such as an anticoagulant medicine, you will have blood tests during treatment.</p><p>Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Pregnancy Vazkepa is not recommended for use during pregnancy unless your doctor advises you to take it.</p><p>Breast-feeding Vazkepa is not recommended for use while breast-feeding as the effect on your baby is not known. Your doctor will help you to weigh up the benefit of treatment against any risk to your breast-feeding baby.</p><p>Fertility Talk with your doctor about fertility during treatment.</p><p>Driving and using machines This medicine is unlikely to affect your ability to drive or use tools or machines.</p><p>Vazkepa contains maltitol, sorbitol and soya lecithin</p><p>Maltitol (E965 ii) If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>Sorbitol (E420 ii) This medicine contains 83 mg sorbitol in each capsule.</p><p>Sorbitol is a source of fructose. If your doctor has told you that you have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you take this medicine.</p><p>Soya lecithin This medicine contains soya lecithin. If you are allergic to soya or peanut, do not use this medicine.</p></div>
</text>
</section>
<section>
<title value="3. How to take vazkepa"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take vazkepa"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Do not change your dose without talking to your doctor.</p><p>How to open bottle Push down the screw cap and turn it anticlockwise.</p><p>How much to take The recommended dose is two capsules by mouth, twice a day, with or after a meal.</p><p>Swallow the capsules whole; Do not break, crush, dissolve or chew the capsules.</p><p>Use in elderly There is no need to change the dose in elderly patients. They can take the usual recommended dose.</p><p>If you take more Vazkepa than you should If you accidentally take more capsules than your doctor has prescribed, contact your doctor or pharmacist for advice.</p><p>If you forget to take Vazkepa If you miss a dose, take it as soon as you remember. However if you missed taking the medicine for a whole day, just take your next scheduled dose. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>If you stop taking Vazkepa Do not stop taking this medicine until you have spoken with your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Contact your doctor</p><ul><li>if you get heart palpitations or irregular heartbeat. These could be symptoms of a serious condition known as atrial fibrillation. This is a common side effect (may affect up to 1 in 10 people):</li><li>if you bruise easily or cannot stop bleeding. This is a very common side effect (may affect more than 1 in 10 people). Your risk of bleeding may increase if you are also taking an anticoagulant medicine.</li></ul><p>Get medical help if you get any of the following side effects. These symptoms could be due to a serious condition known as hypersensitivity which can happen at any time during treatment. This is an uncommon side effect (may affect up to 1 in 100 people)</p><ul><li>difficulty breathing</li><li>tightening or scratching of the throat</li><li>swelling of the lips</li><li>hives (raised bumps on the skin)</li><li>rash and an itchy skin</li><li>stomach pain or cramps</li><li>diarrhoea</li><li>nausea and vomiting Other side effects that may occur</li></ul><p>Common side effects (may affect up to 1 in 10 people):</p><ul><li>swelling of your hands, arms, legs and feet</li><li>pain in muscles, bones or joints</li><li>gout (painful swelling in the joints because of a build up of uric acid)</li><li>rash</li><li>constipation</li><li>burping</li></ul><p>Uncommon side effect (may affect up to 1 in 100 people)</p><ul><li>bad taste in the mouth</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store vazkepa"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store vazkepa"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the bottle label or blister carton after EXP. The expiry date refers to the last day of that month.</p><p>Store below 30 C.</p><p>Bottle: keep the bottle tightly closed in order to protect from moisture. Blister pack: store in the original package in order to protect from moisture.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Vazkepa contains</p><ul><li>The active substance is icosapent ethyl. Each Vazkepa capsule contains 998 mg of icosapent ethyl.</li><li>The other ingredients are * all-rac-alpha-tocopherol, gelatin, glycerol, liquid maltitol (E965 ii), liquid sorbitol (non- crystallising) (E420 ii), purified water and soya lecithin (see section 2 Vazkepa contains maltitol, sorbitol and soya lecithin ). * printing ink: titanium dioxide, propylene glycol, hypromellose.</li></ul><p>What Vazkepa looks like and contents of the pack</p><p>In this pack you will find oblong soft capsules, 25 x 10 mm, printed with IPE in white ink, with a light yellow to amber shell containing a colourless to pale yellow liquid.</p><p>The bottles containing 120 capsules are white 300-cc, high density polyethylene (HDPE) with a child- resistant polypropylene heat induction sealed closure. Pack size of one bottle or three bottles per carton.</p><p>The blister packs contain 4x2 capsules in PVC/PCTFE/Al perforated unit dose blisters.</p><p>Marketing Authorisation Holder Amarin Pharmaceuticals Ireland Limited<br/>88 Harcourt Street Dublin 2, D02DKIreland</p><p>Manufacturer MIAS Pharma Limited Suite 1, Stafford House, Strand Road Portmarnock,<br/>D13 WCIreland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Amarin Pharmaceuticals Ireland Limited T l/Tel: <a href="mailto:0800-75AmarinConnect@amarincorp.eu">0800-75AmarinConnect@amarincorp.eu</a></p><p>Lietuva Amarin Pharmaceuticals Ireland Limited Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Amarin Pharmaceuticals Ireland Limited Te .: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Luxembourg/Luxemburg Amarin Pharmaceuticals Ireland Limited T l/Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>esk republika Amarin Pharmaceuticals Ireland Limited Tlf: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Magyarorsz g Amarin Pharmaceuticals Ireland Limited Tel.: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Danmark Amarin Pharmaceuticals Ireland Limited Tlf: <a href="mailto:+46-84-4685AmarinConnect@amarincorp.eu">+46-84-4685AmarinConnect@amarincorp.eu</a></p><p>Malta Amarin Pharmaceuticals Ireland Limited Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Deutschland Amarin Germany GmbH Tel: <a href="mailto:0800-0008AmarinConnect@amarincorp.eu">0800-0008AmarinConnect@amarincorp.eu</a></p><p>Nederland Amarin Pharmaceuticals Ireland Limited Tel: <a href="mailto:0800-0228AmarinConnect@amarincorp.eu">0800-0228AmarinConnect@amarincorp.eu</a></p><p>Eesti Amarin Pharmaceuticals Ireland Limited Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Norge Amarin Pharmaceuticals Ireland Limited Tlf: +46 84 468 <a href="mailto:5AmarinConnect@amarincorp.eu">5AmarinConnect@amarincorp.eu</a></p><p>Amarin Pharmaceuticals Ireland Limited<br/>: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>sterreich Amarin Pharmaceuticals Ireland Limited<br/>Tel: <a href="mailto:0800-281AmarinConnect@amarincorp.eu">0800-281AmarinConnect@amarincorp.eu</a></p><p>Espa a Amarin Pharmaceuticals Ireland Limited<br/>Polska Amarin Pharmaceuticals Ireland Limited<br/>Tel: <a href="mailto:900806AmarinConnect@amarincorp.eu">900806AmarinConnect@amarincorp.eu</a></p><p>Tel.: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>France Amarin Pharmaceuticals Ireland Limited<br/>T l: <a href="mailto:0800-991AmarinConnect@amarincorp.eu">0800-991AmarinConnect@amarincorp.eu</a></p><p>Portugal Amarin Pharmaceuticals Ireland Limited<br/>Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Hrvatska Amarin Pharmaceuticals Ireland Limited<br/>Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Rom nia Amarin Pharmaceuticals Ireland Limited<br/>Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Ireland Amarin Pharmaceuticals Ireland Limited<br/>Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Slovenija Amarin Pharmaceuticals Ireland Limited<br/>Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>sland Amarin Pharmaceuticals Ireland Limited<br/>S mi: <a href="mailto:+46-84-4685AmarinConnect@amarincorp.eu">+46-84-4685AmarinConnect@amarincorp.eu</a></p><p>Slovensk republika Amarin Pharmaceuticals Ireland Limited<br/>Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Italia Amarin Pharmaceuticals Ireland Limited<br/>Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Suomi/Finland Amarin Pharmaceuticals Ireland Limited<br/>Puh/Tel: <a href="mailto:+46-84-4685AmarinConnect@amarincorp.eu">+46-84-4685AmarinConnect@amarincorp.eu</a></p><p>Amarin Pharmaceuticals Ireland Limited<br/>: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>Sverige Amarin Pharmaceuticals Ireland Limited<br/>Tel: <a href="mailto:+46-84-4685AmarinConnect@amarincorp.eu">+46-84-4685AmarinConnect@amarincorp.eu</a></p><p>Latvija Amarin Pharmaceuticals Ireland Limited<br/>Tel: +353(0)<a href="mailto:16915AmarinConnect@amarincorp.eu">16915AmarinConnect@amarincorp.eu</a></p><p>United Kingdom (Northern Ireland) Amarin Pharmaceuticals Ireland Limited<br/>Tel: <a href="mailto:0800-0478AmarinConnect@amarincorp.eu">0800-0478AmarinConnect@amarincorp.eu</a></p><p>This leaflet was last revised in .</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp96431077feaab94e628cf99788cf8afd"/>
<resource>
<MedicinalProductDefinition>
<id value="mp96431077feaab94e628cf99788cf8afd"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp96431077feaab94e628cf99788cf8afd"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp96431077feaab94e628cf99788cf8afd</b></p><a name="mp96431077feaab94e628cf99788cf8afd"> </a><a name="hcmp96431077feaab94e628cf99788cf8afd"> </a><a name="mp96431077feaab94e628cf99788cf8afd-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1524/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Vazkepa 998 mg soft capsules</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/20/1524/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Vazkepa 998 mg soft capsules"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
